OncoMatch/Clinical Trials/NCT07106671
A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma
Is NCT07106671 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Siltuximab for crs - cytokine release syndrome.
Treatment: Siltuximab — This is a prospective Phase II study evaluating Siltuximab for CRS and ICANS after CAR-T infusion in multiple myeloma patients.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Prior therapy
Must have received: CAR-T cell therapy
after CAR-T treatment
Lab requirements
Blood counts
Platelet count <75,000/μL, absolute neutrophil count <1,000/μL, or hemoglobin <60 g/L at screening [excluded]
Kidney function
Creatinine clearance <30 mL/min [excluded]
Liver function
ALT or AST >3× ULN, or bilirubin >2× ULN [excluded]
Cardiac function
Known severe cardiac conditions, including NYHA class III/IV heart failure, uncontrolled angina, arrhythmia, or hypertension, myocardial infarction within 6 months, or other uncontrolled/severe cardiovascular diseases, including prior cerebrovascular events with residual deficits [excluded]
Creatinine clearance <30 mL/min. Platelet count <75,000/μL, absolute neutrophil count <1,000/μL, or hemoglobin <60 g/L at screening. ALT or AST >3× ULN, or bilirubin >2× ULN. Known severe cardiac conditions, including NYHA class III/IV heart failure, uncontrolled angina, arrhythmia, or hypertension, myocardial infarction within 6 months, or other uncontrolled/severe cardiovascular diseases, including prior cerebrovascular events with residual deficits.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify